Show simple item record

dc.contributor.authorNanton, Ven_US
dc.contributor.authorAppleton, Ren_US
dc.contributor.authorDale, Jen_US
dc.contributor.authorRoscoe, Jen_US
dc.contributor.authorHamborg, Ten_US
dc.contributor.authorAhmedzai, SHen_US
dc.contributor.authorArvanitis, TNen_US
dc.contributor.authorBadger, Den_US
dc.contributor.authorJames, Nen_US
dc.contributor.authorMendelsohn, Ren_US
dc.contributor.authorKhan, Oen_US
dc.contributor.authorParashar, Den_US
dc.contributor.authorPatel, Pen_US
dc.date.accessioned2020-03-27T16:31:24Z
dc.date.issued2017-07-28en_US
dc.identifier.citationJMIR research protocols, 2017, 6 (7), pp. e147 - ?en_US
dc.identifier.issn1929-0748en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3554
dc.identifier.eissn1929-0748en_US
dc.identifier.doi10.2196/resprot.7667en_US
dc.description.abstractBACKGROUND:The potential of technology to aid integration of care delivery systems is being explored in a range of contexts across a variety of conditions in the United Kingdom. Prostate cancer is the most common cancer in UK men. With a 10-year survival rate of 84%, there is a need to explore innovative methods of care that are integrated between primary health care providers and specialist teams in order to address long-term consequences of the disease and its treatment as well as to provide continued monitoring for recurrence. OBJECTIVE:Our aim was to test the feasibility of a randomized controlled trial to compare a model of prostate cancer continuing and follow-up care integration, underpinned by digital technology, with usual care in terms of clinical and cost-effectiveness, patient-reported outcomes, and experience. METHODS:A first phase of the study has included development of an online adaptive prostate specific Holistic Needs Assessment system (HNA), training for primary care-based nurses, training of an IT peer supporter, and interviews with health care professionals and men with prostate cancer to explore views of their care, experience of technology, and views of the proposed intervention. In Phase 2, men in the intervention arm will complete the HNA at home to help identify and articulate concerns and share them with their health care professionals, in both primary and specialist care. Participants in the control arm will receive usual care. Outcomes including quality of life and well-being, prostate-specific concerns, and patient enablement will be measured 3 times over a 9-month period. RESULTS:Findings from phase 1 indicated strong support for the intervention among men, including those who had had little experience of digital technology. Men expressed a range of views on ways that the online system might be used within a clinical pathway. Health care professionals gave valuable feedback on how the output of the assessment might be presented to encourage engagement and uptake by clinical teams. Recruitment to the second phase of the study, the feasibility trial, commenced March 2017. CONCLUSIONS:To our knowledge, this study is the first in the United Kingdom to trial an online holistic needs assessment for men with prostate cancer, with data shared between patients and primary and secondary care providers. This study addresses recommendations in recent policy documents promoting the importance of data sharing and enhanced communication between care providers as a basis for care integration. We anticipate that this model of care will ultimately provide important benefits for both patients and the National Health Service. TRIAL REGISTRATION:International Standard Randomized Controlled Trial Number (ISRCTN): 31380482; http://www.isrctn.com/ISRCTN31380482 (Archived by WebCite at http://www.webcitation.org/6s8I42u5N).en_US
dc.formatElectronicen_US
dc.format.extente147 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleIntegrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-05-08en_US
rioxxterms.versionofrecord10.2196/resprot.7667en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2017-07-28en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJMIR research protocolsen_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.publication-statusPublisheden_US
pubs.volume6en_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate and Bladder Cancer Researchen_US
dc.contributor.icrauthorJames, Nicholasen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/